Is telmisartan safe for use during breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Telmisartan Should Not Be Used During Breastfeeding

Telmisartan is contraindicated during breastfeeding and should be avoided—alternative antihypertensive agents that are safe for lactation should be used instead.

Why Telmisartan Is Unsafe for Breastfeeding

The FDA drug label explicitly states that nursing women should not breastfeed during treatment with telmisartan due to potential serious adverse reactions in the breastfed infant, including hypotension, hyperkalemia, and renal impairment 1. While there is no human data on telmisartan presence in breast milk, animal studies show telmisartan concentrations in rat milk at 1.5 to 2 times those found in plasma 1.

All angiotensin receptor blockers (ARBs), including telmisartan, are classified as medications to avoid during lactation according to multiple authoritative guidelines 2. The 2020 Hypertension Canada guidelines specifically list ARBs under "Medications to avoid (Grade C)" for lactation 2.

The European Society of Cardiology guidelines assign ARBs (including telmisartan specifically) an FDA risk category D for breastfeeding, indicating evidence of risk that outweighs potential benefits 3. The JNC 7 guidelines from 2003 explicitly state that "ACEIs and ARBs should be avoided on the basis of reports of adverse fetal and neonatal renal effects" 4.

Safe Alternatives for Breastfeeding Mothers

Instead of telmisartan, first-line antihypertensive agents safe for breastfeeding include:

  • Labetalol (Grade D recommendation)
  • Methyldopa (Grade D recommendation)
  • Long-acting nifedipine (Grade D recommendation)
  • Enalapril (Grade D recommendation)
  • Captopril (Grade D recommendation)

These agents are recommended by Hypertension Canada 2020 guidelines specifically for lactation 2. The 2025 Circulation guidelines provide additional detail, noting that nifedipine XL has a relative infant dose (RID) of 2.3-3.4%, enalapril 1.1%, and labetalol 3.6%—all well below the 10% safety threshold 5.

Clinical Approach

If a breastfeeding mother is currently on telmisartan:

  1. Switch immediately to one of the safe alternatives listed above
  2. Do not continue telmisartan even briefly during breastfeeding
  3. Prioritize ACE inhibitors (enalapril, captopril) or calcium channel blockers (nifedipine) as first-line alternatives, as these have established safety profiles with low breast milk transfer 2, 5

Important Caveats

While ACE inhibitors are recommended for lactation, there is a theoretical concern about hypotension in premature infants 2. Beta-blockers like labetalol may theoretically cause neonatal bradycardia, so neonatal heart rate monitoring may be warranted 2. However, these theoretical risks are far preferable to the documented serious risks of ARB exposure.

The case report of neonatal acute renal failure following maternal telmisartan exposure 6 underscores the real-world danger of ARB use during the perinatal period, though this case involved pregnancy exposure rather than breastfeeding specifically.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.